Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 5;14(7):1080-1090.
doi: 10.2215/CJN.08140718. Epub 2019 Mar 12.

Clinical Pharmacology of Antibiotics

Affiliations
Review

Clinical Pharmacology of Antibiotics

Rachel F Eyler et al. Clin J Am Soc Nephrol. .

Abstract

Antimicrobial pharmacology and its effect on prescribing is quite complex. Selecting an antibiotic that will optimally treat an infection while minimizing adverse effects and the development of resistance is only the first step, as one must also consider the patient's individual pharmacokinetic alterations and the pharmacodynamic properties of the drug when prescribing it as well. Patients with CKD may have alterations in their protein binding, volumes of distribution, kidney clearance, and nonrenal clearance that necessitates antibiotic dose adjustments to prevent the development of toxicity. Knowledge of a drug's pharmacodynamics, defined as the relationship between drug exposure and antibacterial efficacy, provides some guidance regarding the optimal way to make dose adjustments. Different pharmacodynamic goals, such as maximizing the time that free (unbound) drug concentrations spend above the minimum inhibitory concentration (MIC) for time dependent drugs (e.g., β-lactams) or maximizing the free peak-to-MIC ratio for concentration-dependent antibiotics (e.g., aminoglycosides), require different adjustment strategies; for instance, decreasing the dose while maintaining normal dosing frequency or giving normal (or even larger) doses less frequently, respectively. Patients receiving hemodialysis have other important prescribing considerations as well. The nephrologist or patient may prefer to receive antibiotics that can be administered intravenously toward the end of a dialysis session. Additionally, newer dialysis technologies and filters can increase drug removal more than originally reported. This review will discuss the place in therapy, mechanism of action, pharmacokinetic, pharmacodynamic, and other pharmacologic considerations encountered when prescribing commonly used antibiotics in patients with chronic kidney disease or ESKD.

Keywords: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Kidney Failure, Chronic; Lactams; Metabolic Clearance Rate; Microbial Sensitivity Tests; Protein Binding; Renal Insufficiency, Chronic; antibiotics; chronic renal disease; end-stage renal disease; hemodialysis; pharmacodynamics; pharmacokinetics; pharmacology; renal dialysis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Pharmacodynamic parameters on a concentration–time curve. Peak:MIC is the parameter to optimize for concentration-dependent antibiotics. Time>MIC is the parameter to optimize for time-dependent antibiotics.
Figure 2.
Figure 2.
Mechanisms of antibiotic classes.

References

    1. Dalrymple LS, Go AS: Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1487–1493, 2008 - PMC - PubMed
    1. Chavers BM, Solid CA, Gilbertson DT, Collins AJ: Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J Am Soc Nephrol 18: 952–959, 2007 - PubMed
    1. Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN: Clinical pharmacokinetics in kidney disease: Application to rational design of dosing regimens. Clin J Am Soc Nephrol 13: 1254–1263, 2018 - PMC - PubMed
    1. Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM: Clinical pharmacokinetics in kidney disease: Fundamental principles. Clin J Am Soc Nephrol 13: 1085–1095, 2018 - PMC - PubMed
    1. Eyler RF, Mueller BA: Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease. Adv Chronic Kidney Dis 17: 392–403, 2010 - PubMed

MeSH terms